Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.
|Original language||English (US)|
|Number of pages||3|
|Journal||Oncology (Williston Park, N.Y.)|
|Issue number||9 Suppl 8|
|State||Published - Sep 2003|
ASJC Scopus subject areas
- Cancer Research